CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Short Interest Update

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) was the target of a significant decrease in short interest in the month of December. As of December 31st, there was short interest totalling 150,000 shares, a decrease of 97.9% from the December 15th total of 7,300,000 shares. Currently, 16.5% of the company’s stock are short sold. Based on an average daily volume of 906,000 shares, the days-to-cover ratio is presently 0.2 days.

CERo Therapeutics Trading Up 2.7 %

Shares of CERO opened at $3.04 on Monday. CERo Therapeutics has a 1-year low of $2.83 and a 1-year high of $1,280.00. The firm has a fifty day simple moving average of $11.89 and a two-hundred day simple moving average of $13.26.

Insiders Place Their Bets

In other news, major shareholder Bioventures Opportunities G. Yk sold 8,505 shares of the business’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $11.00, for a total value of $93,555.00. Following the completion of the transaction, the insider now owns 205,333 shares in the company, valued at $2,258,663. The trade was a 3.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders have sold 64,300 shares of company stock worth $529,409. 18.00% of the stock is currently owned by company insiders.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.